Enhanced Sulfonated Polystyrene Derivatives for Improved Cat Flu Treatment

The present invention relates to enhanced sulfonated polystyrene derivatives for the treatment and prophylaxis of cat flu, offering improved efficacy, retention, and delivery.

The original patent disclosed the use of sulfonated polystyrene derivatives for cat flu treatment, but had limitations in terms of retention at the site of infection, delivery, and efficacy. The present inventive concept addresses these limitations by introducing novel formulations, delivery devices, and combinations with other agents.

The new claims describe a system for treating cat flu comprising a sulfonated polystyrene derivative of formula I, formulated with a mucoadhesive excipient to enhance retention at the site of infection, and a delivery device for administering the formulation to a subject in need thereof. Additionally, a method for prophylaxis of cat flu is disclosed, comprising administering a sulfonated polystyrene derivative of formula I in a slow-release formulation to provide sustained protection against infection. Further, a composition for treating cat flu is described, comprising a sulfonated polystyrene derivative of formula I and an anti-inflammatory agent, formulated for oral administration and reducing inflammation in the respiratory tract. A kit for treating cat flu is also disclosed, comprising a sulfonated polystyrene derivative of formula I, a delivery device, and instructions for use, with the option to include a diagnostic test for detecting feline calicivirus or feline herpesvirus. Lastly, a method for enhancing the efficacy of a sulfonated polystyrene derivative of formula I in treating cat flu is described, comprising administering the derivative in combination with an immunomodulator to stimulate the immune response of the subject.

The new claims introduce novel and non-obvious features, including the use of mucoadhesive excipients, slow-release formulations, and combinations with anti-inflammatory agents and immunomodulators, which provide improved efficacy, retention, and delivery compared to the original patent.

Alternative embodiments of the inventive concept could include different mucoadhesive excipients, varying slow-release formulations, and combinations with other agents, such as antibiotics or antivirals. Additionally, the sulfonated polystyrene derivative could be formulated for different routes of administration, such as topical or injectable.

The enhanced sulfonated polystyrene derivatives have significant commercial potential in the veterinary pharmaceutical industry, particularly in the treatment and prophylaxis of cat flu. The target market includes veterinary clinics, animal hospitals, and pet owners, with potential for expansion into other animal health applications.